1,447 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
AEGON NV 2017 Q1 - Results - Earnings Call Slides https://seekingalpha.com/article/4072122-aegon-nv-2017-q1-results-earnings-call-slides?source=feed_sector_financial May 11, 2017 - The following slide deck was published by AEGON NV in conjunction with their 2017 Q1 earnings call.
Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better https://www.fool.com/investing/2017/09/05/gilead-sciences-couldnt-have-timed-its-splash-into.aspx?source=iedfolrf0000001 Sep 05, 2017 - The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.
5 Tough Questions for Gilead Sciences About the Kite Pharma Acquisition https://www.fool.com/investing/2017/09/11/5-tough-questions-for-gilead-sciences-about-the-ki.aspx?source=iedfolrf0000001 Sep 11, 2017 - Gilead Sciences CEO and oncology chief take on direct questions about why buying Kite was the right move.
3 Reasons Celgene's Investors Should Applaud the Juno Therapeutics Buyout https://www.fool.com/investing/2018/01/27/3-reasons-why-the-juno-thearapeutics-buyout-makes.aspx?source=iedfolrf0000001 Jan 27, 2018 - Right product, right price, right time. What more can you ask for?
TomTom NV (TMOAF) CEO Harold Goddijn on Q2 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4187787-tomtom-nv-tmoaf-ceo-harold-goddijn-q2-2018-results-earnings-call-transcript?source=feed_all_articles Jul 17, 2018 - TomTom NV (OTCPK:TMOAF) Q2 2018 Earnings Conference Call July 17, 2018, 08:00 ET Executives Bruno Priuli - IR Harold Goddijn - Co-Founder, Chairman & CEO Taco Titulaer - CFO Analysts Francois Bouv
QUAD GRAPHICS (QUAD) - Profit Tracks http://www.zacks.com/research/screening/tracks/highlight.php?id=4948&cid=CS-ZC--4948 Apr 26, 2012 - QUAD GRAPHICS
Novartis' (NVS) Promacta Label Further Expanded in U.S. http://www.zacks.com/stock/news/187863/novartis-nvs-promacta-label-further-expanded-in-us?cid=CS-ZC-FT-187863 Aug 26, 2015 - Novartis (NVS) with partner Ligand (LGND) announced that the FDA has approved the use of Promacta in children between 1 to 6 years of age with chronic ITP.
Novartis' Farydak Gets EU Approval for Multiple Myeloma http://www.zacks.com/stock/news/189134/novartis-farydak-gets-eu-approval-for-multiple-myeloma?cid=CS-ZC-FT-189134 Sep 07, 2015 - Novartis' (NVS) Farydak (plus Velcade and dexamethasone) gets EU approval for relapsed and/or refractory multiple myeloma in treatment-experienced patients.
Aduro-Incyte in Clinical Trial Agreement for Ovarian Cancer http://www.zacks.com/stock/news/189800/aduro-incyte-in-clinical-trial-agreement-for-ovarian-cancer?cid=CS-ZC-FT-189800 Sep 11, 2015 - Aduro (ADRO) signed a clinical study agreement with Incyte (INCY) to evaluate CRS-207, in combination with Incyte's epacadostat, in patients with ovarian cancer.
Mylan NV Presents at Morgan Stanley Healthcare Brokers Conference (Transcript) http://seekingalpha.com/article/3518926-mylan-nv-presents-at-morgan-stanley-healthcare-brokers-conference-transcript?source=feed_tag_transcripts Sep 17, 2015 - Mylan NV (NASDAQ:MYL) Morgan Stanley Healthcare Conference Call September 17, 2015 2:40 PM ET Executives Heather Bresch - Chief Executive Officer John Sheehan - CFO, EVP, Principal Financial & Acc

Pages: 12345678910...145

<<<Page 5>